AcquisitionOther
Roivant Sciences Ltd. acquired Telavant Including Rights to Novel TL1A Directed Antibody
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Roivant Sciences Ltd. -> Telavant Including Rights to Novel TL1A Directed Antibody · $7.1 billion
This is one of many examples of Roivant furthering its mission to accelerate the development and commercialization of medicines that matter while delivering value to patients and shareholders alike,” said Matt Gline, CEO of Roivant.
Open source record (SEC) ↗